- Drug Coverage
- Hypertrophic Cardiomyopathy (HCM)
- Vaccines: 2023 Year in Review
- Eyecare
- Urothelial Carcinoma
- Women's Health
- Hemophilia
- Heart Failure
- Vaccines
- Neonatal Care
- NSCLC
- Type II Inflammation
- Substance Use Disorder
- Gene Therapy
- Lung Cancer
- Spinal Muscular Atrophy
- HIV
- Post-Acute Care
- Liver Disease
- Pulmonary Arterial Hypertension
- Safety & Recalls
- Biologics
- Asthma
- Atrial Fibrillation
- Type I Diabetes
- RSV
- COVID-19
- Cardiovascular Diseases
- Breast Cancer
- Prescription Digital Therapeutics
- Reproductive Health
- The Improving Patient Access Podcast
- Blood Cancer
- Ulcerative Colitis
- Respiratory Conditions
- Multiple Sclerosis
- Digital Health
- Population Health
- Sleep Disorders
- Biosimilars
- Plaque Psoriasis
- Leukemia and Lymphoma
- Oncology
- Pediatrics
- Urology
- Obstetrics-Gynecology & Women's Health
- Opioids
- Solid Tumors
- Autoimmune Diseases
- Dermatology
- Diabetes
- Mental Health
CMS Estimates Savings for Patients from Medicare Inflation Rebates
Medicare Part B beneficiaries may save between $1 and $3,575 per average dose for the 41 drugs whose prices have risen higher than inflation.
In the second quarter of 2024, the U.S. Department of Health and Human Services (HHS) predicts that an estimated 763,700 people with Medicare Part B will benefit with lowered coinsurance as a result of the inflation rebates required on prescription drugs because of the Inflation Reduction Act.
Between April 1, 2024, and June 30, 2024, beneficiaries may save between $1 and $3,575 per average dose depending on coverage for the 41 drugs (listed below) subject to rebates through Part B whose prices have risen faster than the rate of inflation.
The Inflation Reduction Act requires drug companies to pay rebates to Medicare when prices increase faster than the rate of inflation for certain drugs. The Centers for Medicare & Medicaid Services intends to begin invoicing prescription drug companies for rebates owed to Medicare no later than fall 2025. The rebate amounts paid by drug companies will be deposited in the Federal Supplementary Medical Insurance Trust Fund, which will help ensure the long-term sustainability of the Medicare program for future generations
List of drugs subject to inflation rebate, second quarter 2024
- Abelcet (amphotericin B lipid complex injection): fungal infections, Leadiant Biosciences
- Adcetris (brentuximab vedotin: Hodgkin lymphoma and large cell lymphoma; Seagen/Pfizer
- Akynzeo Capsule (netupitant/palonosetron): chemotherapy induced nausea; Helsinn
- Akynzeo IV (netupitant/palonosetron): chemotherapy induced nausea; Helsinn
- Argatroban (Accord) with HCPCS code J0891: anticoagulant
- Argatroban (Accord) with HCPCS code J0892: anticoagulant
- Argatroban (Auromedics) with HCPCS code J0898: anticoagulant
- Argatroban (Auromedics) with HCPCS code J0899: anticoagulant
- Atgam (immune globulin): aplastic anemia; Pfizer
- Aveed (testosterone): hormone replacement; Endo
- Bicillin C-R (penicillin G benzathine, penicillin G procaine): infections; Pfizer
- Bicillin L-A (penicillin G benzathine): infections; Pfizer
- Blincyto (blinatumomab): acute lymphoblastic leukemia; Amgen
- Chirhostim (hormone): diagnosis of pancreatic dysfunction and cancer; ChiRhoClin
- Crysvita (burosumab-twza): X-linked hypophosphatemia; Kyowa Kirin
- Cytogam (cytomegalovirus immune globulin); to prevent CMV after organ transplant; Kamada
- Dysport (abobotulinumtoxinA): frown lines; Galderma
- Envarsus XR (tacrolimus): to prevent organ rejection; Veloxis Pharmaceuticals
- Fosaprepitant (Teva): nausea and vomiting
- Fragmin (dalteparin): blood thinner; Pfizer
- Hypertet (tetanus immune globulin): prevention of tetanus; Grifols
- Imlygic (talimogene laherparepvec): melanoma; Amgen
- Kepivance (palifermin): to reduce mucositis after chemotherapy; Sobi
- Kymriah (tisagenlecleucel): acute lymphoblastic leukemia; Novartis
- Leukine (sargramostim): bone marrow stimulant; Partner Therapeutics
- Lupron Depot-Ped (leuprorelin): endometriosis, prostate cancer; AbbVie
- Meropenem (B Braun): bacterial infections
- Minocin (minocycline): infections; Torrent Pharmaceuticals
- Nexterone (amiodarone) (Baxter): for heart rhythm problems
- Nipent (pentostatin): leukemia; Pfizer
- Oncaspar (pegaspargase): acute lymphoblastic leukemia; Servier
- Padcev (enfortumab vedotin): bladder cancer; Astellas and Seagen/Pfizer
- Panhematin (hemin): porphyria: Recordati Rare Diseases
- Prolia (denosumab): osteoporosis; Amgen
- Romidepsin (non-lyophilized) T-cell lymphoma
- Signifor LAR (pasireotide): acromegaly and Cushing’s; Recordati Rare Disease
- Sotalol (altathera): arrhythmias
- Sylvant (siltuximab): Castleman’s disease; Recordati Rare Diseases
- Synribo (omacetaxine mepesuccinate): chronic myeloid leukemia; Teva
- Tigan Tigecycline (Accord): antimicrobial
- Tivdak (tisotumab vedotin): cervical cancer; Genmab and Seagen/Pfizer
- Vabomere (meropenem and vaborbactam): urinary tract infections and hospital acquired pneumonia; Melinta
- Xiaflex (collagenase clostridium histolyticum): Peyronie’s disease and Dupuytren’s contracture; Endo
- Zemdri (plazomicin): urinary tract infections; Cipla Therapeutics
DC Roundtable: Patrick Cooney of The Federal Group Drops the Latest on PBM Legislation in Washington
April 11th 2024In this episode of "DC Roundtable," Peter Wehrwein, managing editor of Managed Healthcare Executive, spoke with Patrick Cooney, president of The Federal Group, a lobbying and strategic planning firm in Washington, D.C., about recent developments in Washington concerning PBMs.
Listen
